Pharmacokinetic analysis and pharmacodynamic endpoints, including serum IFN-γ cytokine concentrations and evaluation of changes in both systemic and tumor-associated immune-cell subsets following NHS-IL12 exposure, were assessed. This evidence concerns the gene IFNG and neoplasm.